AR132824A1 - USO TERAPÉUTICO DE ANTICUERPOS ANTI-Ab / TfR BIESPECÍFICOS - Google Patents

USO TERAPÉUTICO DE ANTICUERPOS ANTI-Ab / TfR BIESPECÍFICOS

Info

Publication number
AR132824A1
AR132824A1 ARP240101383A ARP240101383A AR132824A1 AR 132824 A1 AR132824 A1 AR 132824A1 AR P240101383 A ARP240101383 A AR P240101383A AR P240101383 A ARP240101383 A AR P240101383A AR 132824 A1 AR132824 A1 AR 132824A1
Authority
AR
Argentina
Prior art keywords
bispecific anti
therapeutic use
bispecific
tfr antibodies
antibody
Prior art date
Application number
ARP240101383A
Other languages
English (en)
Inventor
Joo Andr Abrantes
David Andrew Agnew
Fabien Alcaraz
Ruth Emma Croney
Carsten Hofmann
Paul Jordan
Gregory Klein
Luka Kulic
Maddalena Marchesi
Hanno Svoboda
Annamarie Vogt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR132824A1 publication Critical patent/AR132824A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se informa un anticuerpo biespecífico que se une específicamente a la proteína Ab humana y al receptor de transferrina humano (anticuerpo anti-Ab / TfR biespecífico) así como el uso de tales anticuerpos biespecíficos como un medicamento en el tratamiento de la enfermedad de Alzheimer, que incluye donde el anticuerpo biespecífico se administra por vía intravenosa a una dosis de 0,2 mg/kg a 7,2 mg/kg una vez cada cuatro semanas.
ARP240101383A 2023-05-31 2024-05-31 USO TERAPÉUTICO DE ANTICUERPOS ANTI-Ab / TfR BIESPECÍFICOS AR132824A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP23/64623 2023-05-31
EPPCT/EP23/79276 2023-10-20
EPPCT/EP24/55668 2024-03-05

Publications (1)

Publication Number Publication Date
AR132824A1 true AR132824A1 (es) 2025-07-30

Family

ID=91375896

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101383A AR132824A1 (es) 2023-05-31 2024-05-31 USO TERAPÉUTICO DE ANTICUERPOS ANTI-Ab / TfR BIESPECÍFICOS

Country Status (11)

Country Link
US (1) US20240417451A1 (es)
EP (1) EP4719471A1 (es)
JP (2) JP7802859B2 (es)
KR (1) KR20260020387A (es)
CN (1) CN121263206A (es)
AR (1) AR132824A1 (es)
AU (1) AU2024283314A1 (es)
IL (1) IL324430A (es)
MX (1) MX2025014083A (es)
TW (1) TW202515904A (es)
WO (1) WO2024246085A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2026119384A1 (en) * 2024-12-04 2026-06-11 F. Hoffmann-La Roche Ag Therapeutic use of bispecific anti-abeta/tfr antibodies
JP2026096188A (ja) * 2024-12-02 2026-06-12 エフ. ホフマン-ラ ロシュ アーゲー 二重特異性抗Aベータ/TfR抗体の治療的使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JP5859148B2 (ja) 2012-03-08 2016-02-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Aβ抗体製剤
JP2014001232A (ja) 2013-09-02 2014-01-09 Janssen Alzheimer Immunotherapy アミロイド原性疾患の処置
AU2016282334B2 (en) * 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CR20230253A (es) * 2020-11-16 2023-07-26 Hoffmann La Roche Glucoformas de fab ricas en manosa
CN115227813A (zh) 2021-04-23 2022-10-25 江苏恒瑞医药股份有限公司 一种含抗Abeta抗体的药物组合物

Also Published As

Publication number Publication date
CN121263206A (zh) 2026-01-02
EP4719471A1 (en) 2026-04-08
MX2025014083A (es) 2026-01-07
WO2024246085A1 (en) 2024-12-05
TW202515904A (zh) 2025-04-16
AU2024283314A1 (en) 2025-11-13
IL324430A (en) 2026-01-01
JP7802859B2 (ja) 2026-01-20
JP2024178124A (ja) 2024-12-24
KR20260020387A (ko) 2026-02-11
JP2026065045A (ja) 2026-04-14
US20240417451A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
MX2020003888A (es) Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
MX2025014083A (es) Uso terapeutico de anticuerpos biespecificos anti proteina beta-amiloide (abeta)/receptor de transferrina (tfr)
US20100209430A1 (en) Method for treating erectile dysfunction
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
US20150023972A1 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
CL2022002093A1 (es) Anticuerpos para usar en terapia.
Harris US maternal mortality continues to worsen
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
CN102343089A (zh) 一种治疗乳癌的医药组成物
Harris CDC: Candida auris fungal infections and drug resistance on the rise
BR112020014849A2 (pt) Anticorpo recombinante isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma de infecção por influenza
Mahboob et al. Large vessel stroke and COVID-19: case report and literature review
Zydb et al. Efficacy of oral ketamine combined with psychotherapy for treatment resistant depression
Harris Drought caused 43 000 deaths in Somalia in 2022, half among children
Hungria et al. Impact of long-term treatment with belantamab mafodotin on safety and efficacy outcomes in patients with relapsed/refractory multiple myeloma in DREAMM-3
Kuter et al. A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
PE20250161A1 (es) Dosis para tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3 en pacientes mayores
Marini et al. Rozanolixizumab treatment patterns in patients with generalised myasthenia gravis: Post hoc analysis
CR20220041A (es) Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab
Harris World on Path to Eliminate AIDS as a Global Threat by 2030
CR20250089A (es) Composiciones para el tratamiento de una enfermedad o trastorno mediado por linfocitos t portadoras del segmento trbv9 dentro del receptor de células t
RU2013124994A (ru) КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
Harris Cold Virus Provided Cross-reactivity Against SARS-CoV-2 in Children
AR131609A1 (es) Método de tratamiento de una enfermedad o trastorno mediado por linfocitos t portadoras del segmento trbv9 dentro del receptor de células t